A 68-year-old obese, nulliparous, hypertensive woman is diagnosed with FIGO Stage IA (myometrial invasion <50%) Grade 1 endometrioid endometrial carcinoma. Adjuvant therapy recommended per current ESGO/ESTRO guidelines is:
- A No adjuvant therapy; surveillance only ✓
- B External beam radiotherapy to whole pelvis
- C Vaginal brachytherapy only
- D Platinum-based chemotherapy
Correct answer: A. No adjuvant therapy; surveillance only
Explanation
ESGO/ESTRO/ESP 2021 guidelines classify Stage IA Grade 1 endometrioid carcinoma without LVSI as 'low risk' — no adjuvant therapy is recommended beyond surgical staging and surveillance. The relapse risk is <5% and adjuvant therapy adds no survival benefit in this group. Vaginal brachytherapy is used for intermediate-risk disease (Stage IB Grade 1–2, or Stage IA Grade 3), while EBRT is reserved for high-intermediate and high-risk groups.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.